Reported 4 days ago
Biotech company Axsome Therapeutics has seen its stock rise by 55% in 2025, driven largely by a successful settlement of a patent lawsuit that secures the exclusivity of its treatment, Auvelity, until at least 2038. With additional therapies in its portfolio and strong projected revenue growth, the company may continue to perform well. Investors who missed the initial surge may still find opportunities worth exploring in Axsome's future prospects.
Source: YAHOO